Lepu Medical to be listed on the SIX Swiss Exchange; Alphamab Oncology, Zelgen Biopharmaceuticals
Sarina Yang ·09/16/2022

Top news story of the day:


Lepu Medical to be listed on the SIX Swiss Exchange


On September 16, Lepu Medical made an announcement regarding the issuance of Global Depositary Receipts (GDRs) and its listing on the SWX Swiss Exchange. The company has determined the final price of the offering to be $12.68 per GDR. The number of GDRs issued this time will be 17,684,396, raising total proceeds to approximately $224 million.


Funds raised will be used primarily for further development of the company's core business and strategic investments, including building overseas R&D centers, production bases and business expansion centers.


Lepu expects the GDR offering to be officially listed on the SWX Swiss Exchange on September 21, 2022.


Founded in 1999, Lepu Medical is one of the first companies in China engaged in the R&D and manufacture of cardiovascular interventional medical devices, like cardiovascular stents, pacemakers, drugs and medical artificial intelligence. In 2009, the company was listed on the A-share Growth Enterprises Market.



In other news:


Alphamab Oncology announced that the FDA granted Fast Track Designation (FTD) to its PD-L1 monoclonal antibody envafolimab (KN035) for the treatment of pleomorphic sarcoma / fibrous histiocytic sarcoma.


Zelgen Biopharmaceuticals announced a successful Phase II clinical trial of its Jaktinib tablets for the treatment of active ankylosing spondylitis.


By Sarina Yang

Keywords: Lepu Medical Alphamab Oncology Zelgen Biopharmaceuticals
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement